世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

創薬における人工知能（AI）市場：提供（ソフトウェア、サービス）、技術（機械学習、深層学習）、用途（循環器、代謝、神経変性）、エンドユーザー（製薬、バイオテクノロジー、CRO）別 - 世界予測（ 2022 - 2027 )


Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts ( 2022 - 2027 )

創薬における人工知能/AI市場は、2022年の6億米ドルから2027年には40億米ドルに達すると予測され、予測期間中のCAGRは45.7%となります。この市場の成長は主に、創薬・開発コストの抑制やこのプロセスにかかる全体... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年6月15日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		193 210 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

創薬における人工知能/AI市場は、2022年の6億米ドルから2027年には40億米ドルに達すると予測され、予測期間中のCAGRは45.7%となります。この市場の成長は主に、創薬・開発コストの抑制やこのプロセスにかかる全体時間の短縮の必要性、クラウドベースのアプリケーションやサービスの採用が増加していることなどの要因によってもたらされています。一方、熟練労働者の不足は、予測期間中、市場の成長をある程度抑制する主な要因となっています。.
「2022年にはサービス分野が主要シェアを占め、予測期間中に最も高い成長を遂げると予想される。
提供に基づいて、創薬におけるAI市場はソフトウェアとサービスに二分されます。サービスセグメントは2022年に世界の創薬におけるAIサービス市場で最大の市場シェアを占めると予想され、予測期間中に最も速いCAGRで成長すると予測されています。これらのサービスに関連する利点と利点、およびエンドユーザーのAIサービスに対する強い需要が、このセグメントのthegrowthの主要因である。

"創薬におけるAI世界市場において、機械学習技術セグメントが最大のシェアを占める"
創薬におけるAI市場は、技術に基づいて、機械学習とその他の技術に区分されます。2021年の世界市場では、機械学習セグメントが最大のシェアを占め、予測期間中に最も高いCAGRで成長すると予測されます。CRO、製薬、バイオテクノロジー企業における機械学習技術の高い採用率と、データセットからインサイトを抽出するこれらの技術の能力により、創薬プロセスの加速に役立つことが、このセグメントの市場成長を支える要因の1つとなっています。

"製薬・バイオテクノロジー企業セグメントは、2022年に市場の最大シェアを占めると予想される"
創薬におけるAI市場は、エンドユーザーごとに、製薬＆バイオテクノロジー企業、CRO、研究所・学術＆政府機関に分けられます。2021年の創薬におけるAI市場では、製薬＆バイオテクノロジー企業分野が最も大きなシェアを占めています。一方、リサーチセンターと学術＆政府機関は、予測期間中に最も高いCAGRを記録すると予想されます。創薬プロセス全体をより時間的・コスト的に効率化するためのAIベースのツールに対する強い需要が、製薬・バイオテクノロジーエンドユーザーセグメントの主要な成長要因となっています。

"2021年、創薬におけるAI市場を支配するのは北米"
世界の創薬におけるAI市場は、北米、欧州、APAC、その他の地域の4つの主要地域に区分されます。2021年、創薬におけるAIは、北米が最大かつ最も成長率の高い地域市場を占めています。米国、カナダ、メキシコで構成される北米は、創薬におけるAIの最大の市場を形成しています。これらの国々は、創薬と開発におけるAI技術の早期採用者である。主要な既存プレイヤーの存在、確立された製薬およびバイオテクノロジー産業、研究開発への高い注力と実質的な投資は、この市場の大きなシェアと高い成長率の主な要因の一部です。

サプライサイドの一次面接の内訳、企業タイプ別、呼称別、地域別。
- 企業タイプ別ティア1 (31%)、ティア2 (28%)、ティア3 (41%)
- 役職別Cレベル(31%)、ディレクターレベル(25%)、その他(44%)
- 地域別北米 (45%)、欧州 (20%)、アジア太平洋 (28%)、RoW (7%)

本市場における主なプレイヤーは、NVIDIA Corporation（米国）、Microsoft Corporation（米国）、Google（米国）、Exscientia（英国）、Schrödinger（米国）、Atomwise,Inc.(米国）、BenevolentAI（英国）、NuMedii（米国）、BERG LLC（米国）、Cloud Pharmaceuticals（米国）、Insilico Medicine（米国）、Cyclica（カナダ）、Deep Genomics（カナダ）、IBM（米国）、BIOAGE（米国）、Valo Health（米国）、Envisagenics（米国）、2XAR（米国）、Owkin,inc.(米国）、XtalPi（米国）、Verge Genomics（米国）、Biovista（米国）、Evaxion Biotech（デンマーク）、Iktos（フランス）、Standigm（韓国）およびBenchSci（カナダ）。プレイヤーは、製品のアップグレード、コラボレーション、契約、パートナーシップ、買収などの有機的および無機的な成長戦略を採用し、オファリングの増加、顧客の満たされていないニーズへの対応、収益性の向上、世界市場での存在感の拡大を図っています。

調査対象範囲
- 当レポートでは、創薬におけるAI市場を、提供、技術、用途、エンドユーザー、地域に基づいて調査しています。
- 市場の成長に影響を与える要因（ドライバー、阻害要因、機会、課題など）を分析しています。
- 利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。
- ミクロ市場の成長動向、展望、創薬におけるAI市場全体への貢献度に関して調査しています。
- レポートでは、5つの主要地域に関して市場セグメントの収益を予測しています。

レポート購入の主なメリット
本レポートは、この市場のリーダー／新規参入者に、市場全体とサブセグメントの収益数値の最も近い近似値に関する情報を提供するのに役立ちます。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、ステークホルダーが創薬におけるAI市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供するのに役立ちます。

ページTOPに戻る


目次

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION 28
1.3.2 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.7 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 2 RESEARCH DESIGN 31
2.2 SECONDARY SOURCES 32
2.2.1 KEY DATA FROM SECONDARY SOURCES 33
2.3 PRIMARY DATA 33
2.3.1 PRIMARY SOURCES 34
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION 35
2.3.2.1 Key industry insights 35
2.4 MARKET SIZE ESTIMATION 36
FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 37
FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY 38
TABLE 1 FACTOR ANALYSIS 40
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022–2027) 40
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 8 TOP-DOWN APPROACH 41
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 9 DATA TRIANGULATION METHODOLOGY 42
TABLE 2 MARKET SIZING ASSUMPTIONS 43
2.6 OVERALL STUDY ASSUMPTIONS 43
2.7 LIMITATIONS 44
2.8 RISK ASSESSMENT 44
TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET 44
3 EXECUTIVE SUMMARY 45
FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION) 45
FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 46
FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 46
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 47
4 PREMIUM INSIGHTS 48
4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW 48
FIGURE 14 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS 48
4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021–2027) 49
FIGURE 15 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 49
4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021) 50
FIGURE 16 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021 50
4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 17 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 MARKET DRIVERS 53
5.2.1.1 Growing number of cross-industry collaborations and partnerships 53
TABLE 4 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019−2021) 53
5.2.1.2 Growing need to control drug discovery & development costs and reduce time involved in drug development 54
5.2.1.3 Patent expiry of several drugs 54
TABLE 5 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2022 54
5.2.2 MARKET RESTRAINTS 55
5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 55
5.2.3 MARKET OPPORTUNITIES 55
5.2.3.1 Growing biotechnology industry 55
5.2.3.2 Emerging markets 56
5.2.3.3 Focus on developing human-aware AI systems 56
5.2.3.4 Growth in the drugs and biologics market despite the COVID-19 pandemic 56
5.2.4 MARKET CHALLENGES 56
5.2.4.1 Limited availability of data sets 56
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 19 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021) 57
5.4 PORTER’S FIVE FORCES ANALYSIS 58
TABLE 6 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 58
5.5 ECOSYSTEM 59
FIGURE 20 AI IN DRUG DISCOVERY MARKET ECOSYSTEM 59
5.6 TECHNOLOGY ANALYSIS 59
5.7 PRICING ANALYSIS 60
5.8 BUSINESS MODELS 60
FIGURE 21 AI IN LIFE SCIENCES: BUSINESS MODELS 61
FIGURE 22 BENEFITS OF HYBRID BUSINESS MODELS 61
FIGURE 23 SPECIALIZATION OF AI COMPANIES OVER TIME 62
5.9 REGULATIONS 63
5.10 CONFERENCES AND WEBINARS 63
5.11 CASE STUDY ANALYSIS 64
5.11.1 CASE STUDY 1 64
5.11.2 CASE STUDY 2 65
6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 66
6.1 INTRODUCTION 67
TABLE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 67
6.2 SOFTWARE 67
6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH 67
TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION) 68
TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 69
6.3 SERVICES 69
6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 69
TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 13 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 14 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 15 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 71
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 72
7.1 INTRODUCTION 73
TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73
7.2 MACHINE LEARNING 73
TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 75
7.2.1 DEEP LEARNING 75
7.2.1.1 Deep learning accelerates the discovery process of life-saving drugs and precision medicine 75
TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 77
7.2.2 SUPERVISED LEARNING 77
7.2.2.1 Supervised learning can be applied in drug repositioning 77
TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 79
7.2.3 REINFORCEMENT LEARNING 79
7.2.3.1 Insilico Medicine is a pioneer in the application of reinforcement learning in drug discovery 79
TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.2.4 UNSUPERVISED LEARNING 81
7.2.4.1 Unsupervised learning can be more unpredictable than alternate models 81
TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 82
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 82
TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 84
7.3 OTHER TECHNOLOGIES 84
TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 43 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 44 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 45 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 86
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION 87
8.1 INTRODUCTION 88
TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88
8.2 IMMUNO-ONCOLOGY 88
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 88
TABLE 47 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT 89
TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 90
8.3 NEURODEGENERATIVE DISEASES 90
8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT 90
TABLE 52 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.4 CARDIOVASCULAR DISEASES 92
8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH 92
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 93
TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
8.5 METABOLIC DISEASES 94
8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT 94
TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 96
8.6 OTHER APPLICATIONS 96
TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 67 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 68 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 98
9.1 INTRODUCTION 99
TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 99
9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI 99
TABLE 70 INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 100
TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 72 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 73 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 74 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 101
9.3 CONTRACT RESEARCH ORGANIZATIONS 102
9.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 102
TABLE 75 INDICATIVE LIST OF COLLABORATIONS WITH CROS 102
TABLE 76 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 102
TABLE 77 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 78 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 79 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 104
9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 104
TABLE 80 INDICATIVE LIST OF RESEARCH COLLABORATIONS 104
TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 104
TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 83 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 84 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 105
10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 106
10.1 INTRODUCTION 107
TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020–2027 (USD MILLION) 107
10.2 NORTH AMERICA 107
FIGURE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 108
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 109
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 109
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 110
10.2.1 US 110
10.2.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US 110
TABLE 91 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET 111
TABLE 92 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 111
TABLE 93 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 112
TABLE 94 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
TABLE 95 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 112
10.2.2 CANADA 113
10.2.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support market growth in Canada 113
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 113
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 114
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 114
10.2.3 MEXICO 115
10.2.3.1 Government initiatives to support market growth in Mexico 115
TABLE 100 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 115
TABLE 101 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 115
TABLE 102 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 103 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 116
10.3 EUROPE 116
FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 117
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 118
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 118
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 119
10.3.1 UK 119
10.3.1.1 UK holds the largest share of the European market 119
TABLE 109 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK 120
TABLE 110 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 120
TABLE 111 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 121
TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 121
10.3.2 GERMANY 122
10.3.2.1 Government support and favorable training programs are key market drivers in Germany 122
TABLE 114 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 122
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 123
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 123
10.3.3 FRANCE 124
10.3.3.1 Strong government support and favorable strategies & initiatives to drive market growth in France 124
TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 124
TABLE 119 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124
TABLE 120 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 125
10.3.4 ITALY 125
10.3.4.1 Presence of a strong pharmaceutical industry in Italy to drive market growth 125
TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 126
TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 126
TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 127
10.3.5 REST OF EUROPE 127
TABLE 126 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 127
TABLE 127 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 128
TABLE 128 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 129 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 128
10.4 ASIA PACIFIC 129
TABLE 130 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 131 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 129
TABLE 132 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130
TABLE 133 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 134 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 130
10.4.1 JAPAN 131
10.4.1.1 Japan dominates the APAC market for AI in drug discovery 131
TABLE 135 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 131
TABLE 136 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 132
TABLE 137 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 132
TABLE 138 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 132
10.4.2 CHINA 133
10.4.2.1 Growing CMO market and cross-industry collaborations are factors responsible for market growth in China 133
TABLE 139 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 133
TABLE 140 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 133
TABLE 141 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 134
TABLE 142 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 134
10.4.3 INDIA 134
10.4.3.1 Steady adoption of AI technologies will drive market growth in India 134
TABLE 143 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 135
TABLE 144 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 135
TABLE 145 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135
TABLE 146 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 136
10.4.4 REST OF ASIA PACIFIC 136
TABLE 147 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 136
TABLE 148 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 137
TABLE 149 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 150 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 137
10.5 REST OF THE WORLD 138
TABLE 151 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 138
TABLE 152 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 138
TABLE 153 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 154 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 139
11 COMPETITIVE LANDSCAPE 140
11.1 OVERVIEW 140
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 140
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET 140
11.3 MARKET RANKING ANALYSIS 141
TABLE 155 AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021 142
11.4 COMPETITIVE BENCHMARKING 143
TABLE 156 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 143
TABLE 157 AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS 143
TABLE 158 AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 144
11.5 COMPETITIVE LEADERSHIP MAPPING 144
11.5.1 STARS 144
11.5.2 EMERGING LEADERS 144
11.5.3 PERVASIVE PLAYERS 145
11.5.4 PARTICIPANTS 145
FIGURE 26 AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021 145
11.6 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES 146
11.6.1 PROGRESSIVE COMPANIES 146
11.6.2 STARTING BLOCKS 146
11.6.3 RESPONSIVE COMPANIES 146
11.6.4 DYNAMIC COMPANIES 146
FIGURE 27 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 147
11.7 COMPETITIVE SITUATIONS AND TRENDS 148
TABLE 159 PRODUCT LAUNCHES 148
TABLE 160 DEALS 148
12 COMPANY PROFILES 151
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS 151
12.1.1 MICROSOFT 151
TABLE 161 MICROSOFT: BUSINESS OVERVIEW 151
FIGURE 28 MICROSOFT: COMPANY SNAPSHOT (2020) 152
TABLE 162 MICROSOFT: DEALS 153
12.1.2 NVIDIA 155
TABLE 163 NVIDIA: BUSINESS OVERVIEW 155
FIGURE 29 NVIDIA: COMPANY SNAPSHOT (2022) 156
TABLE 164 NVIDIA: EXPANSIONS 157
TABLE 165 NVIDIA: DEALS 157
12.1.3 EXSCIENTIA 158
TABLE 166 EXSCIENTIA: BUSINESS OVERVIEW 158
FIGURE 30 EXSCIENTIA: COMPANY SNAPSHOT (2021) 158
12.1.4 GOOGLE 162
TABLE 167 GOOGLE: BUSINESS OVERVIEW 162
FIGURE 31 GOOGLE: COMPANY SNAPSHOT (2021) 163
12.1.5 BENEVOLENTAI 165
TABLE 168 BENEVOLENTAI: BUSINESS OVERVIEW 165
12.1.6 NUMEDII, INC. 167
TABLE 169 NUMEDII: BUSINESS OVERVIEW 167
12.1.7 BERG, LLC 169
TABLE 170 BERG, LLC: BUSINESS OVERVIEW 169
12.1.8 ATOMWISE 171
TABLE 171 ATOMWISE: BUSINESS OVERVIEW 171
12.1.9 DEEP GENOMICS 173
TABLE 172 DEEP GENOMICS: BUSINESS OVERVIEW 173
12.1.10 INSILICO MEDICINE 175
TABLE 173 INSILICO MEDICINE: BUSINESS OVERVIEW 175
12.1.11 SCHRÖDINGER, INC. 177
TABLE 174 SCHRÖDINGER: BUSINESS OVERVIEW 177
FIGURE 32 SCHRÖDINGER: COMPANY SNAPSHOT (2021) 178
12.1.12 IBM 181
TABLE 175 IBM: BUSINESS OVERVIEW 181
FIGURE 33 IBM: COMPANY SNAPSHOT (2022) 182
TABLE 176 IBM: DEALS 183
TABLE 177 IBM: OTHER DEVELOPMENTS 183
12.2 OTHER PLAYERS 184
12.2.1 CYCLICA INC. 184
12.2.2 CLOUD PHARMACEUTICALS 184
12.2.3 BIOAGE 185
12.2.4 ENVISAGENICS 185
12.2.5 TWOXAR, INC. (ARIA PHARMACEUTICALS) 186
12.2.6 OWKIN, INC. 186
12.2.7 XTALPI, INC. 187
12.2.8 VERGE GENOMICS 187
12.2.9 IKTOS 188
12.2.10 EVAXION BIOTECH 188
12.2.11 STANDIGM 189
12.2.12 VALO HEALTH 190
12.2.13 BIOVISTA 190
12.2.14 BENCHSCI 191
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
13 APPENDIX 192
13.1 DISCUSSION GUIDE 192
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 195
13.3 AVAILABLE CUSTOMIZATIONS 197
13.4 RELATED REPORTS 197
13.5 AUTHOR DETAILS 198

　

ページTOPに戻る


　

Summary

The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growt at certain extent over the forecast period. .
“Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period”
On the basis of offering, the AI in drug discovery market is bifurcated into software and services. the services segment expected to account for the largest market share of the global AI in drug discovery services market in 2022, and expected to grow fastest CAGR during the forecast period. The advantages and benefits associated with these services and the strong demand for AI services among end users are the key factors for thegrowth of this segment.

“Machine learning technology segment accounted for the largest share of the global AI in drug discovery market”
On the basis of technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. High adoption of machine learning technology among CRO, pharmaceutical and biotechnology companies and capability of these technologies to extract insights from data sets, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

“Pharmaceutical & biotechnology companies segment expectd to hold the largest share of the market in 2022”
On the basis of end user, the AI in drug discovery market is divided into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. In 2021, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market. On the other hand, research centers and academic & government institutes are expected to witness the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is the key growth factor of pharmaceutical and biotechnology end-user segment.

“North America to dominate the AI in drug discovery market in 2021”
The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2021, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the major factors responsible for the large share and high growth rate of this market.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
• By Designation: C-level (31%), Director-level (25%), and Others (44%)
• By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (7%)

Prominent players in this market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage
• The report studies the AI in drug discovery market based on offering, technology, application, end user, and region
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market
• The report forecasts the revenue of market segments with respect to five major regions

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the AI in drug discovery market and provides them information on key market drivers, restraints, challenges, and opportunities.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION 28
1.3.2 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.7 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 2 RESEARCH DESIGN 31
2.2 SECONDARY SOURCES 32
2.2.1 KEY DATA FROM SECONDARY SOURCES 33
2.3 PRIMARY DATA 33
2.3.1 PRIMARY SOURCES 34
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION 35
2.3.2.1 Key industry insights 35
2.4 MARKET SIZE ESTIMATION 36
FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 37
FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY 38
TABLE 1 FACTOR ANALYSIS 40
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022–2027) 40
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 8 TOP-DOWN APPROACH 41
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 9 DATA TRIANGULATION METHODOLOGY 42
TABLE 2 MARKET SIZING ASSUMPTIONS 43
2.6 OVERALL STUDY ASSUMPTIONS 43
2.7 LIMITATIONS 44
2.8 RISK ASSESSMENT 44
TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET 44
3 EXECUTIVE SUMMARY 45
FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION) 45
FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 46
FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 46
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 47
4 PREMIUM INSIGHTS 48
4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW 48
FIGURE 14 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS 48
4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021–2027) 49
FIGURE 15 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 49
4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021) 50
FIGURE 16 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021 50
4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 17 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 MARKET DRIVERS 53
5.2.1.1 Growing number of cross-industry collaborations and partnerships 53
TABLE 4 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019−2021) 53
5.2.1.2 Growing need to control drug discovery & development costs and reduce time involved in drug development 54
5.2.1.3 Patent expiry of several drugs 54
TABLE 5 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2022 54
5.2.2 MARKET RESTRAINTS 55
5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 55
5.2.3 MARKET OPPORTUNITIES 55
5.2.3.1 Growing biotechnology industry 55
5.2.3.2 Emerging markets 56
5.2.3.3 Focus on developing human-aware AI systems 56
5.2.3.4 Growth in the drugs and biologics market despite the COVID-19 pandemic 56
5.2.4 MARKET CHALLENGES 56
5.2.4.1 Limited availability of data sets 56
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 19 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021) 57
5.4 PORTER’S FIVE FORCES ANALYSIS 58
TABLE 6 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 58
5.5 ECOSYSTEM 59
FIGURE 20 AI IN DRUG DISCOVERY MARKET ECOSYSTEM 59
5.6 TECHNOLOGY ANALYSIS 59
5.7 PRICING ANALYSIS 60
5.8 BUSINESS MODELS 60
FIGURE 21 AI IN LIFE SCIENCES: BUSINESS MODELS 61
FIGURE 22 BENEFITS OF HYBRID BUSINESS MODELS 61
FIGURE 23 SPECIALIZATION OF AI COMPANIES OVER TIME 62
5.9 REGULATIONS 63
5.10 CONFERENCES AND WEBINARS 63
5.11 CASE STUDY ANALYSIS 64
5.11.1 CASE STUDY 1 64
5.11.2 CASE STUDY 2 65
6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 66
6.1 INTRODUCTION 67
TABLE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 67
6.2 SOFTWARE 67
6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH 67
TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION) 68
TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 69
6.3 SERVICES 69
6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 69
TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 13 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 14 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 15 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 71
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 72
7.1 INTRODUCTION 73
TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73
7.2 MACHINE LEARNING 73
TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 75
7.2.1 DEEP LEARNING 75
7.2.1.1 Deep learning accelerates the discovery process of life-saving drugs and precision medicine 75
TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 77
7.2.2 SUPERVISED LEARNING 77
7.2.2.1 Supervised learning can be applied in drug repositioning 77
TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 79
7.2.3 REINFORCEMENT LEARNING 79
7.2.3.1 Insilico Medicine is a pioneer in the application of reinforcement learning in drug discovery 79
TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.2.4 UNSUPERVISED LEARNING 81
7.2.4.1 Unsupervised learning can be more unpredictable than alternate models 81
TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION) 82
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 82
TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 84
7.3 OTHER TECHNOLOGIES 84
TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 43 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 44 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 45 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 86
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION 87
8.1 INTRODUCTION 88
TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88
8.2 IMMUNO-ONCOLOGY 88
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 88
TABLE 47 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT 89
TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 90
8.3 NEURODEGENERATIVE DISEASES 90
8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT 90
TABLE 52 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.4 CARDIOVASCULAR DISEASES 92
8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH 92
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 93
TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
8.5 METABOLIC DISEASES 94
8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT 94
TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 96
8.6 OTHER APPLICATIONS 96
TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 67 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 68 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 98
9.1 INTRODUCTION 99
TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 99
9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI 99
TABLE 70 INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 100
TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 72 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 73 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 74 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 101
9.3 CONTRACT RESEARCH ORGANIZATIONS 102
9.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 102
TABLE 75 INDICATIVE LIST OF COLLABORATIONS WITH CROS 102
TABLE 76 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 102
TABLE 77 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 78 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 79 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 104
9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 104
TABLE 80 INDICATIVE LIST OF RESEARCH COLLABORATIONS 104
TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 104
TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 83 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 84 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 105
10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 106
10.1 INTRODUCTION 107
TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020–2027 (USD MILLION) 107
10.2 NORTH AMERICA 107
FIGURE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 108
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 109
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 109
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 110
10.2.1 US 110
10.2.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US 110
TABLE 91 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET 111
TABLE 92 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 111
TABLE 93 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 112
TABLE 94 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
TABLE 95 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 112
10.2.2 CANADA 113
10.2.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support market growth in Canada 113
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 113
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 114
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 114
10.2.3 MEXICO 115
10.2.3.1 Government initiatives to support market growth in Mexico 115
TABLE 100 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 115
TABLE 101 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 115
TABLE 102 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 103 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 116
10.3 EUROPE 116
FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 117
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 118
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 118
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 119
10.3.1 UK 119
10.3.1.1 UK holds the largest share of the European market 119
TABLE 109 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK 120
TABLE 110 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 120
TABLE 111 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 121
TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 121
10.3.2 GERMANY 122
10.3.2.1 Government support and favorable training programs are key market drivers in Germany 122
TABLE 114 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 122
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 123
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 123
10.3.3 FRANCE 124
10.3.3.1 Strong government support and favorable strategies & initiatives to drive market growth in France 124
TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 124
TABLE 119 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124
TABLE 120 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 125
10.3.4 ITALY 125
10.3.4.1 Presence of a strong pharmaceutical industry in Italy to drive market growth 125
TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 126
TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 126
TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 127
10.3.5 REST OF EUROPE 127
TABLE 126 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 127
TABLE 127 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 128
TABLE 128 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 129 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 128
10.4 ASIA PACIFIC 129
TABLE 130 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 131 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 129
TABLE 132 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130
TABLE 133 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 134 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 130
10.4.1 JAPAN 131
10.4.1.1 Japan dominates the APAC market for AI in drug discovery 131
TABLE 135 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 131
TABLE 136 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 132
TABLE 137 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 132
TABLE 138 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 132
10.4.2 CHINA 133
10.4.2.1 Growing CMO market and cross-industry collaborations are factors responsible for market growth in China 133
TABLE 139 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 133
TABLE 140 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 133
TABLE 141 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 134
TABLE 142 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 134
10.4.3 INDIA 134
10.4.3.1 Steady adoption of AI technologies will drive market growth in India 134
TABLE 143 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 135
TABLE 144 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 135
TABLE 145 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135
TABLE 146 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 136
10.4.4 REST OF ASIA PACIFIC 136
TABLE 147 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 136
TABLE 148 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 137
TABLE 149 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 150 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 137
10.5 REST OF THE WORLD 138
TABLE 151 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 138
TABLE 152 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 138
TABLE 153 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 154 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 139
11 COMPETITIVE LANDSCAPE 140
11.1 OVERVIEW 140
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 140
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET 140
11.3 MARKET RANKING ANALYSIS 141
TABLE 155 AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021 142
11.4 COMPETITIVE BENCHMARKING 143
TABLE 156 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 143
TABLE 157 AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS 143
TABLE 158 AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 144
11.5 COMPETITIVE LEADERSHIP MAPPING 144
11.5.1 STARS 144
11.5.2 EMERGING LEADERS 144
11.5.3 PERVASIVE PLAYERS 145
11.5.4 PARTICIPANTS 145
FIGURE 26 AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021 145
11.6 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES 146
11.6.1 PROGRESSIVE COMPANIES 146
11.6.2 STARTING BLOCKS 146
11.6.3 RESPONSIVE COMPANIES 146
11.6.4 DYNAMIC COMPANIES 146
FIGURE 27 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 147
11.7 COMPETITIVE SITUATIONS AND TRENDS 148
TABLE 159 PRODUCT LAUNCHES 148
TABLE 160 DEALS 148
12 COMPANY PROFILES 151
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS 151
12.1.1 MICROSOFT 151
TABLE 161 MICROSOFT: BUSINESS OVERVIEW 151
FIGURE 28 MICROSOFT: COMPANY SNAPSHOT (2020) 152
TABLE 162 MICROSOFT: DEALS 153
12.1.2 NVIDIA 155
TABLE 163 NVIDIA: BUSINESS OVERVIEW 155
FIGURE 29 NVIDIA: COMPANY SNAPSHOT (2022) 156
TABLE 164 NVIDIA: EXPANSIONS 157
TABLE 165 NVIDIA: DEALS 157
12.1.3 EXSCIENTIA 158
TABLE 166 EXSCIENTIA: BUSINESS OVERVIEW 158
FIGURE 30 EXSCIENTIA: COMPANY SNAPSHOT (2021) 158
12.1.4 GOOGLE 162
TABLE 167 GOOGLE: BUSINESS OVERVIEW 162
FIGURE 31 GOOGLE: COMPANY SNAPSHOT (2021) 163
12.1.5 BENEVOLENTAI 165
TABLE 168 BENEVOLENTAI: BUSINESS OVERVIEW 165
12.1.6 NUMEDII, INC. 167
TABLE 169 NUMEDII: BUSINESS OVERVIEW 167
12.1.7 BERG, LLC 169
TABLE 170 BERG, LLC: BUSINESS OVERVIEW 169
12.1.8 ATOMWISE 171
TABLE 171 ATOMWISE: BUSINESS OVERVIEW 171
12.1.9 DEEP GENOMICS 173
TABLE 172 DEEP GENOMICS: BUSINESS OVERVIEW 173
12.1.10 INSILICO MEDICINE 175
TABLE 173 INSILICO MEDICINE: BUSINESS OVERVIEW 175
12.1.11 SCHRÖDINGER, INC. 177
TABLE 174 SCHRÖDINGER: BUSINESS OVERVIEW 177
FIGURE 32 SCHRÖDINGER: COMPANY SNAPSHOT (2021) 178
12.1.12 IBM 181
TABLE 175 IBM: BUSINESS OVERVIEW 181
FIGURE 33 IBM: COMPANY SNAPSHOT (2022) 182
TABLE 176 IBM: DEALS 183
TABLE 177 IBM: OTHER DEVELOPMENTS 183
12.2 OTHER PLAYERS 184
12.2.1 CYCLICA INC. 184
12.2.2 CLOUD PHARMACEUTICALS 184
12.2.3 BIOAGE 185
12.2.4 ENVISAGENICS 185
12.2.5 TWOXAR, INC. (ARIA PHARMACEUTICALS) 186
12.2.6 OWKIN, INC. 186
12.2.7 XTALPI, INC. 187
12.2.8 VERGE GENOMICS 187
12.2.9 IKTOS 188
12.2.10 EVAXION BIOTECH 188
12.2.11 STANDIGM 189
12.2.12 VALO HEALTH 190
12.2.13 BIOVISTA 190
12.2.14 BENCHSCI 191
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
13 APPENDIX 192
13.1 DISCUSSION GUIDE 192
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 195
13.3 AVAILABLE CUSTOMIZATIONS 197
13.4 RELATED REPORTS 197
13.5 AUTHOR DETAILS 198

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（SaaS（Software as a Service））の最新刊レポート

MarketsandMarkets社のSaaS（Software as a Service）分野での最新刊レポート

本レポートと同じKEY WORD（application cardiovascular）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14　10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.